Newly Opened Phase 3 Study for Low Grade Serous Ovarian Cancer-Recording

Video Transcription

Video Summary

In a recent webinar, Dr. Grisham and Dr. Banerjee introduced a Phase III study, RAMP301, for low-grade serous ovarian cancer. They discussed a novel combination of avutumetinib and dafactinib, showing promising results in the Phase I FRAME study with a response rate of 46%. The discussion focused on the importance of developing new treatments for rare gynecological cancers and the potential of targeted therapies like MEK inhibitors. They shared data from RAMP201, highlighting a 45% response rate with the combination therapy. The webinar also touched on NGS testing for MAP kinase alterations and potential use of CDK4/6 inhibitors and aromatase inhibitors for patients with low-grade serous ovarian cancer. The RAMP301 study is now open globally, offering patients the option to be randomized to the combination therapy or physician's choice of treatment. Participants discussed the relevance of gene testing and treatment options in recurrent low-grade serous ovarian cancer, emphasizing the need for more effective treatments and ongoing research in this field.

Keywords

Phase III study

RAMP301

low-grade serous ovarian cancer

avutumetinib

dafactinib

MEK inhibitors

NGS testing